Alethio Therapeutics raises $90 million Series A for blood cancer antibody

Alethio Therapeutics, a biotechnology start-up spun out of the University of Oxford, announced on Thursday, 5 November 2026 that it has raised $90 million (about £67 million) in a Series A funding round. The round was co-led by Sofinnova Partners and RA Capital, with founding investor Oxford Science Enterprises taking part and support from Cancer Research Horizons and the University of Oxford. The company plans to use the money to take its lead drug candidate, an antibody called ATX-011 for the blood cancer essential thrombocythaemia, through early-stage clinical studies.

Essential thrombocythaemia is a form of MPN in which the body makes too many platelets, the blood cells that help clotting. ATX-011 is designed, according to the company, to speed up the removal of platelets from the blood and possibly to act on the cells that keep the disease going. Alethio describes the approach as "mutation-agnostic", meaning it is meant to work regardless of which genetic change drives a patient's disease. These are the company's claims about a drug that has not yet been tested in people, and they will only be proved or disproved in clinical trials.

For investors and founders, the round is a sign of how much money specialist investors are still willing to put into a single early drug programme from a university laboratory. A $90 million Series A is large for a company whose lead drug has not entered human testing. The structure, with a university investment arm as founding backer and specialist life-science investors leading the round, is the model that many university spin-outs follow.

Alethio's plan is narrow by design: one antibody, one disease to start with, and a path that runs from early studies to readiness for a Phase 3 trial, the large, late-stage test that regulators usually require before approving a drug.

Peepals calculation: The three reported amounts imply exchange rates of about £0.74 per US dollar (£67m ÷ $90m ≈ 0.74) and about €0.89 per US dollar (€80.46m ÷ $90m ≈ 0.89), which is why the same round appears with different headline numbers in different places. With the company founded in 2021, the round comes about five years after its creation (2026 − 2021 = 5). Our calculation from the reported figures.

Short-term: The money lets Alethio complete the laboratory and safety work needed before it can apply to regulators to begin human trials, and then fund the first clinical studies.

Long-term: If ATX-011 proves safe and effective, it could offer patients with essential thrombocythaemia a new kind of treatment; if it fails in trials, investors lose much of their stake, as is common in early drug development.

Who is affected: Patients with essential thrombocythaemia and other MPNs and their doctors; Alethio's staff and investors; the University of Oxford and its research partners; and biotech founders and investors, including in India, who watch such rounds as a guide to what specialist investors will fund.

What to watch next: the start of studies needed before regulatory filings, which the company expects in the first half of 2027, and later the start of Phase 1/2a trials of ATX-011.

Questions and Answers